“With many of us spending more time sitting as a result of the pandemic, this research is more important than ever”
Improving the health of people with Type 1 Diabetes (T1D) through a simple and practical change in lifestyle is being explored by a team of UK researchers.
Dr. Matthew Campbell at the University of Sunderland is leading a study into whether breaking up prolonged sitting time with short frequent bouts of light-intensity walking can improve glucose levels and reduce risk factors associated with T1D complications.
Working in collaboration with the University of Cambridge and the University of Leeds, the 18-month project has received funding in excess of £100k from the national charity Diabetes UK.
Research has already shown there are benefits with these small changes to people with and without Type 2 Diabetes (T2D) in lowering glucose levels across the whole day, including mealtimes and during the night.
However, to date there has been no research in this area for those living with T1D, in particular the risk of dangerous glucose lows (hypoglycaemia), or whether this approach can lower the risk of developing complications which include heart and blood vessel disease, nerve damage, kidney damage, eye damage and foot damage.
Dr. Campbell, Principal Investigator in Human Metabolism in the Faculty of Health Sciences and Wellbeing, explained: “Our research will address an urgent unmet need for those with T1D. Sitting for long periods of time is harmful to our health. In people with diabetes, this has been shown to contribute to poorer glucose control and an increased risk of developing diabetes complications.
“The NHS and Diabetes UK recommend and encourage all people with diabetes to become more physically active; people with T1D are at least as inactive as the general population.
“While you may meet the physical activity guidelines, if you sit for long periods of time, you may still fall into the category of having a sedentary lifestyle.
“Simple and acceptable methods that enable people to incorporate physical activity more easily into everyday life and reduce the amount of time spent sitting is urgently needed for people with T1D.”
In the UK, T1D affects approximately 400,000 people which is around 10% of the total number of people living with diabetes.
The study will include monitoring glucose levels using the latest technology and collecting blood samples from a group of more than 30 T1D volunteers, to discover if short frequent bouts of light-intensity walking improve glucose levels and any risk factors associated with diabetes complications in people with T1D.
Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: “Dr. Campbell’s research will investigate whether people with T1D could benefit from making subtle lifestyle changes. With many of us spending more time sitting as a result of the pandemic, this research is more important than ever. We’re proud to be funding this work at such a critical time, and hope it will lead to new, more achievable ways for people with type 1 diabetes to manage their glucose levels, reduce their risk of serious complications and protect their overall health.”
Dr. Campbell, who has published extensively in the area of diabetes and glucose regulation, says when physical activity is promoted by healthcare professionals, it is often exercise, rather than lower-intensity activities tends to be encouraged to promote movement across the day. But, for most inactive people, exercise can often be viewed as daunting or unachievable and its promotion can discourage individuals from becoming active. However, he adds that reducing the time spent inactive and focusing on lower-intensity activities is often viewed as achievable and a good starting point for many.
He says: “For some people with T1D this approach may be viewed as an important stepping-stone towards more regular participation in physical activity or exercise, whereas for others, it may be a simple and acceptable intervention to achieve better glucose control in its own right and reduce the risk of future complications.”
It’s hoped that the study results may influence treatment decisions and clinical consensus, where suitable.
The study will also provide vital proof-of-concept evidence to inform larger outcome trials that more comprehensively establish safety and effectiveness over the longer-term in a more diverse group of people with T1D (for example, in people with established diabetes complications, different fitness levels, or individuals struggling with weight-management).